Development of a treatment applicable to a large number of COVID-19 patients

With special interest in those who present risk factors (e.g. with previous respiratory pathologies and elderly population).

The objective of TRANCOR is to determine the immunomodulatory effect (ability of a certain substance to stimulate or depress the immune system by helping the body to fight infection) of natural origin, in patients with COVID-19. To this end, trials on infection models will be carried out, as well as coordination with a trial on COVID-19 patients currently underway in several hospitals.

Principal Investigator: Pablo Botella Asunción (ITQ)

We use cookies on this site to improve your user experience. More info. ACEPTAR

Aviso de cookies